Rezera IPO Seeks $217 Million to Fund Inflammation Drugs

The Boston developer's lead candidate has finished mid-stage trials, but its cash runs only into January 2027.

Updated on Nov. 5, 2026 in Biotech

Vector editorial illustration of unlabeled glass vials clustered on a laboratory bench in warm coral and cream tones, evoking early-stage drug development. — Boston drug developer Rezera is seeking up to $216.7 million in a Nasdaq IPO, with its lead inflammation candidate past mid-stage trials and cash lasting only into January 2027. AI Illustration. Upload story photo >

Live Poll

Would you invest in a newly listed biotech company's IPO?

Boston drug developer Rezera launched its US initial public offering roadshow on November 5, 2026, seeking up to $216.7 million by offering 16.7 million shares priced between $11 and $13 apiece. The offering is an IPO of a company that is still research-stage: its lead candidate, ruvonoflast, has completed mid-stage trials but has not been approved.

Why it matters

The filing lands in a busy window for biotech listings, with Aspen Neuroscience and Bambusa Therapeutics having gone public in New York last week and Swiss developer Windward Bio having filed for a New York IPO last month. Rezera's partnership with GSK, including a right of first negotiation and a clinical advisory board agreement, signals that large drugmakers are positioning themselves early around inflammation-focused cardiovascular and neurologic programs.

The IPO terms are set by a company-issued offering document, with the $3.9 million cash position at June 30 set against a projected runway into January 2027. Against roughly $200 million raised since 2016, the company's cash balance is small, which points to near-term capital needs as its lead candidate moves forward.

The players

Rezera

Boston-based drug developer building a portfolio of inflammation-targeting therapies for cardiovascular and neurologic disease, with ruvonoflast as its lead candidate.

GSK

Global drugmaker that agreed to buy up to $25 million of Rezera shares and holds a right of first negotiation and clinical advisory role with the company.

Jefferies

Investment bank serving as a joint bookrunner on Rezera's IPO.

TD Cowen

Investment bank serving as a joint bookrunner on Rezera's IPO.

Cantor

Investment bank serving as a joint bookrunner on Rezera's IPO.

The details

Rezera develops drugs aimed at the inflammatory processes that drive cardiovascular and neurologic disease, meaning the immune-system responses that damage blood vessels and nerve tissue over time. Its lead candidate, ruvonoflast, has completed mid-stage clinical trials, which test safety and early evidence of effect in patients before larger late-stage studies. The company is pursuing the IPO on the Nasdaq under the symbol RZRA, with Jefferies, TD Cowen, and Cantor as joint bookrunners and Wedbush PacGrow as lead manager.

June 30: Rezera reported $3.9 million in cash and cash equivalents.
Early November 2026: Rezera struck a right of first negotiation and clinical advisory board agreement with GSK.
Late October 2026: Aspen Neuroscience and Bambusa Therapeutics went public in New York.
November 5, 2026: Rezera launched its US IPO roadshow.
January 2027: Rezera's cash is expected to support operations into this month.

The Tech Race

Rezera joins Aspen Neuroscience, Bambusa Therapeutics, and Windward Bio in a cluster of biotech listings in New York over the past several weeks. Its differentiator is a mid-stage inflammation program paired with an early GSK relationship, setting it against peers that are racing to show clinical progress before their cash runs short.

For patients, the offering matters only indirectly: ruvonoflast is still in mid-stage trials, so no approved treatment is available. Investors can buy into the company once it prices and lists on the Nasdaq under RZRA, while patients with cardiovascular or neurologic inflammation will need to wait for later-stage trial results.

The takeaway

Watch whether Rezera prices within the $11 to $13 range and whether it reaches the $270 million valuation at the top of the marketed range. Its cash runway into January 2027 makes the next financing or late-stage trial announcement a key marker to track.

What happens next

Rezera's offering pricing and its first trading day on the Nasdaq under RZRA are expected to follow the roadshow, with final proceeds and valuation set at pricing.